Phase 1 VIPER-101 abstract reports 88% overall response rate and 75% complete response rate with durable CD5-negative T-cell reconstitution Senza5 CART5 holds FDA RMAT and Orphan Drug designations; the Company plans to advance the program into a pivotal study LampTAC is a novel, in vivo degrader technology and preclinical indings...
https://bioadvance.com/vittoria-biotherapeutics-to-present-phase-1-results-for-senza5-cart5-in-t-cell-lymphoma-in-an-oral-session-and-lamptac-degrader-platform-data-in-a-poster-session-at-ash-2026/?utm_source=rss&utm_medium=rss&utm_campaign=vittoria-biotherapeutics-to-present-phase-1-results-for-senza5-cart5-in-t-cell-lymphoma-in-an-oral-session-and-lamptac-degrader-platform-data-in-a-poster-session-at-ash-2026